No biomarker
|
Triple Negative Breast Cancer
|
No biomarker
|
Triple Negative Breast Cancer
|
pembrolizumab Sensitive: A1 - Approval
Merck (MSD) Press Release - 4 days (NewA1)
|
pembrolizumab Sensitive: A1 - Approval
Merck (MSD) Press Release - 4 days - (New A1)
|
HRD + BRCA wild-type
|
Triple Negative Breast Cancer
|
HRD + BRCA wild-type
|
Triple Negative Breast Cancer
|
D19466 Sensitive: C3 – Early Trials
Ther Adv Med Oncol - 3 weeks (NewC3)
|
D19466 Sensitive: C3 – Early Trials
Ther Adv Med Oncol - 3 weeks - (New C3)
|
HRD + BRCA wild-type
|
Triple Negative Breast Cancer
|
HRD + BRCA wild-type
|
Triple Negative Breast Cancer
|
carboplatin Sensitive: C3 – Early Trials
Ther Adv Med Oncol - 3 weeks (NewC3)
|
carboplatin Sensitive: C3 – Early Trials
Ther Adv Med Oncol - 3 weeks - (New C3)
|
HRD
|
Triple Negative Breast Cancer
|
HRD
|
Triple Negative Breast Cancer
|
D19466 Sensitive: C3 – Early Trials
Ther Adv Med Oncol - 3 weeks (NewC3)
|
D19466 Sensitive: C3 – Early Trials
Ther Adv Med Oncol - 3 weeks - (New C3)
|
HRD + BRCA wild-type
|
Triple Negative Breast Cancer
|
HRD + BRCA wild-type
|
Triple Negative Breast Cancer
|
cisplatin Sensitive: C3 – Early Trials
Ther Adv Med Oncol - 3 weeks (NewC3)
|
cisplatin Sensitive: C3 – Early Trials
Ther Adv Med Oncol - 3 weeks - (New C3)
|
HRD
|
Triple Negative Breast Cancer
|
HRD
|
Triple Negative Breast Cancer
|
carboplatin Sensitive: C3 – Early Trials
Ther Adv Med Oncol - 3 weeks (NewC3)
|
carboplatin Sensitive: C3 – Early Trials
Ther Adv Med Oncol - 3 weeks - (New C3)
|
ALDH1A1 positive
|
Triple Negative Breast Cancer
|
ALDH1A1 positive
|
Triple Negative Breast Cancer
|
EPZ-5676 Sensitive: D – Preclinical
Clin Cancer Res - 3 weeks (NewD)
|
EPZ-5676 Sensitive: D – Preclinical
Clin Cancer Res - 3 weeks - (New D)
|
PD-L1 expression
|
Triple Negative Breast Cancer
|
PD-L1 expression
|
Triple Negative Breast Cancer
|
atezolizumab Sensitive: A1 - Approval
|
atezolizumab Sensitive: A1 - Approval
|
PD-L1 expression
|
Triple Negative Breast Cancer
|
PD-L1 expression
|
Triple Negative Breast Cancer
|
pembrolizumab Sensitive: A1 - Approval
|
pembrolizumab Sensitive: A1 - Approval
|
No biomarker
|
Triple Negative Breast Cancer
|
No biomarker
|
Triple Negative Breast Cancer
|
sacituzumab govitecan-hziy Sensitive: A1 - Approval
|
sacituzumab govitecan-hziy Sensitive: A1 - Approval
|
No biomarker
|
Triple Negative Breast Cancer
|
No biomarker
|
Triple Negative Breast Cancer
|
CaT Sensitive: A2 - Guideline
|
CaT Sensitive: A2 - Guideline
|
BRCA2 mutation
|
Triple Negative Breast Cancer
|
BRCA2 mutation
|
Triple Negative Breast Cancer
|
cisplatin Sensitive: A2 - Guideline
|
cisplatin Sensitive: A2 - Guideline
|
BRCA1 mutation
|
Triple Negative Breast Cancer
|
BRCA1 mutation
|
Triple Negative Breast Cancer
|
cisplatin Sensitive: A2 - Guideline
|
cisplatin Sensitive: A2 - Guideline
|
BRCA2 mutation
|
Triple Negative Breast Cancer
|
BRCA2 mutation
|
Triple Negative Breast Cancer
|
carboplatin Sensitive: A2 - Guideline
|
carboplatin Sensitive: A2 - Guideline
|
BRCA1 mutation
|
Triple Negative Breast Cancer
|
BRCA1 mutation
|
Triple Negative Breast Cancer
|
carboplatin Sensitive: A2 - Guideline
|
carboplatin Sensitive: A2 - Guideline
|
BRCA2 mutation
|
Triple Negative Breast Cancer
|
BRCA2 mutation
|
Triple Negative Breast Cancer
|
gemcitabine Sensitive: A2 - Guideline
|
gemcitabine Sensitive: A2 - Guideline
|
BRCA1 mutation
|
Triple Negative Breast Cancer
|
BRCA1 mutation
|
Triple Negative Breast Cancer
|
gemcitabine Sensitive: A2 - Guideline
|
gemcitabine Sensitive: A2 - Guideline
|
BRCA2 mutation
|
Triple Negative Breast Cancer
|
BRCA2 mutation
|
Triple Negative Breast Cancer
|
capecitabine Sensitive: A2 - Guideline
|
capecitabine Sensitive: A2 - Guideline
|
BRCA1 mutation
|
Triple Negative Breast Cancer
|
BRCA1 mutation
|
Triple Negative Breast Cancer
|
capecitabine Sensitive: A2 - Guideline
|
capecitabine Sensitive: A2 - Guideline
|
BRCA2 mutation
|
Triple Negative Breast Cancer
|
BRCA2 mutation
|
Triple Negative Breast Cancer
|
vinorelbine tartrate Sensitive: A2 - Guideline
|
vinorelbine tartrate Sensitive: A2 - Guideline
|
BRCA1 mutation
|
Triple Negative Breast Cancer
|
BRCA1 mutation
|
Triple Negative Breast Cancer
|
vinorelbine tartrate Sensitive: A2 - Guideline
|
vinorelbine tartrate Sensitive: A2 - Guideline
|
BRCA2 mutation
|
Triple Negative Breast Cancer
|
BRCA2 mutation
|
Triple Negative Breast Cancer
|
eribulin mesylate Sensitive: A2 - Guideline
|
eribulin mesylate Sensitive: A2 - Guideline
|
BRCA1 mutation
|
Triple Negative Breast Cancer
|
BRCA1 mutation
|
Triple Negative Breast Cancer
|
eribulin mesylate Sensitive: A2 - Guideline
|
eribulin mesylate Sensitive: A2 - Guideline
|
BRCA2 mutation
|
Triple Negative Breast Cancer
|
BRCA2 mutation
|
Triple Negative Breast Cancer
|
pegylated liposomal doxorubicin Sensitive: A2 - Guideline
|
pegylated liposomal doxorubicin Sensitive: A2 - Guideline
|
BRCA1 mutation
|
Triple Negative Breast Cancer
|
BRCA1 mutation
|
Triple Negative Breast Cancer
|
pegylated liposomal doxorubicin Sensitive: A2 - Guideline
|
pegylated liposomal doxorubicin Sensitive: A2 - Guideline
|
BRCA2 mutation
|
Triple Negative Breast Cancer
|
BRCA2 mutation
|
Triple Negative Breast Cancer
|
paclitaxel Sensitive: A2 - Guideline
|
paclitaxel Sensitive: A2 - Guideline
|
BRCA2 mutation
|
Triple Negative Breast Cancer
|
BRCA2 mutation
|
Triple Negative Breast Cancer
|
olaparib Sensitive: A2 - Guideline
|
olaparib Sensitive: A2 - Guideline
|
BRCA1 mutation
|
Triple Negative Breast Cancer
|
BRCA1 mutation
|
Triple Negative Breast Cancer
|
olaparib Sensitive: A2 - Guideline
|
olaparib Sensitive: A2 - Guideline
|
BRCA2 mutation
|
Triple Negative Breast Cancer
|
BRCA2 mutation
|
Triple Negative Breast Cancer
|
talazoparib Sensitive: A2 - Guideline
|
talazoparib Sensitive: A2 - Guideline
|
BRCA1 mutation
|
Triple Negative Breast Cancer
|
BRCA1 mutation
|
Triple Negative Breast Cancer
|
talazoparib Sensitive: A2 - Guideline
|
talazoparib Sensitive: A2 - Guideline
|
No biomarker
|
Triple Negative Breast Cancer
|
No biomarker
|
Triple Negative Breast Cancer
|
carboplatin Sensitive: A2 - Guideline
|
carboplatin Sensitive: A2 - Guideline
|
BRCA2 mutation
|
Triple Negative Breast Cancer
|
BRCA2 mutation
|
Triple Negative Breast Cancer
|
PARP inhibitor Sensitive: A2 - Guideline
|
PARP inhibitor Sensitive: A2 - Guideline
|
BRCA1 mutation
|
Triple Negative Breast Cancer
|
BRCA1 mutation
|
Triple Negative Breast Cancer
|
PARP inhibitor Sensitive: A2 - Guideline
|
PARP inhibitor Sensitive: A2 - Guideline
|
BRCA2 mutation
|
Triple Negative Breast Cancer
|
BRCA2 mutation
|
Triple Negative Breast Cancer
|
doxorubicin hydrochloride Sensitive: A2 - Guideline
|
doxorubicin hydrochloride Sensitive: A2 - Guideline
|
BRCA1 mutation
|
Triple Negative Breast Cancer
|
BRCA1 mutation
|
Triple Negative Breast Cancer
|
doxorubicin hydrochloride Sensitive: A2 - Guideline
|
doxorubicin hydrochloride Sensitive: A2 - Guideline
|
BRCA1 mutation
|
Triple Negative Breast Cancer
|
BRCA1 mutation
|
Triple Negative Breast Cancer
|
paclitaxel Sensitive: A2 - Guideline
|
paclitaxel Sensitive: A2 - Guideline
|
PD-L1 expression
|
Triple Negative Breast Cancer
|
PD-L1 expression
|
Triple Negative Breast Cancer
|
Immunotherapy Sensitive: A2 - Guideline
|
Immunotherapy Sensitive: A2 - Guideline
|
BRCA1 mutation
|
Triple Negative Breast Cancer
|
BRCA1 mutation
|
Triple Negative Breast Cancer
|
CaT Sensitive: B - Late Trials
|
CaT Sensitive: B - Late Trials
|
No biomarker
|
Triple Negative Breast Cancer
|
No biomarker
|
Triple Negative Breast Cancer
|
IPI-549 Sensitive: B - Late Trials
|
IPI-549 Sensitive: B - Late Trials
|
AKT1 mutation
|
Triple Negative Breast Cancer
|
AKT1 mutation
|
Triple Negative Breast Cancer
|
RG7440 Sensitive: B - Late Trials
|
RG7440 Sensitive: B - Late Trials
|
PTEN mutation
|
Triple Negative Breast Cancer
|
PTEN mutation
|
Triple Negative Breast Cancer
|
RG7440 Sensitive: B - Late Trials
|
RG7440 Sensitive: B - Late Trials
|
PD-L1 overexpression
|
Triple Negative Breast Cancer
|
PD-L1 overexpression
|
Triple Negative Breast Cancer
|
pembrolizumab Sensitive: B - Late Trials
|
pembrolizumab Sensitive: B - Late Trials
|
PIK3CA mutation
|
Triple Negative Breast Cancer
|
PIK3CA mutation
|
Triple Negative Breast Cancer
|
RG7440 Sensitive: B - Late Trials
|
RG7440 Sensitive: B - Late Trials
|
BRCA2 mutation
|
Triple Negative Breast Cancer
|
BRCA2 mutation
|
Triple Negative Breast Cancer
|
carboplatin + paclitaxel Sensitive: B - Late Trials
|
carboplatin + paclitaxel Sensitive: B - Late Trials
|
BRCA2 mutation
|
Triple Negative Breast Cancer
|
BRCA2 mutation
|
Triple Negative Breast Cancer
|
ABT-888 Sensitive: B - Late Trials
|
ABT-888 Sensitive: B - Late Trials
|
BRCA1 mutation
|
Triple Negative Breast Cancer
|
BRCA1 mutation
|
Triple Negative Breast Cancer
|
ABT-888 Sensitive: B - Late Trials
|
ABT-888 Sensitive: B - Late Trials
|
CDKN2B mutation
|
Triple Negative Breast Cancer
|
CDKN2B mutation
|
Triple Negative Breast Cancer
|
atezolizumab Sensitive: B - Late Trials
|
atezolizumab Sensitive: B - Late Trials
|
CDKN2A mutation
|
Triple Negative Breast Cancer
|
CDKN2A mutation
|
Triple Negative Breast Cancer
|
atezolizumab Sensitive: B - Late Trials
|
atezolizumab Sensitive: B - Late Trials
|
BRCA2 mutation
|
Triple Negative Breast Cancer
|
BRCA2 mutation
|
Triple Negative Breast Cancer
|
atezolizumab Sensitive: B - Late Trials
|
atezolizumab Sensitive: B - Late Trials
|
BRCA1 mutation
|
Triple Negative Breast Cancer
|
BRCA1 mutation
|
Triple Negative Breast Cancer
|
atezolizumab Sensitive: B - Late Trials
|
atezolizumab Sensitive: B - Late Trials
|
ER positive + HER-2 negative
|
Triple Negative Breast Cancer
|
ER positive + HER-2 negative
|
Triple Negative Breast Cancer
|
cyclophosphamide + thiotepa Sensitive: B - Late Trials
|
cyclophosphamide + thiotepa Sensitive: B - Late Trials
|
TMB-H + PD-L1 expression
|
Triple Negative Breast Cancer
|
TMB-H + PD-L1 expression
|
Triple Negative Breast Cancer
|
atezolizumab Sensitive: B - Late Trials
|
atezolizumab Sensitive: B - Late Trials
|
No biomarker
|
Triple Negative Breast Cancer
|
No biomarker
|
Triple Negative Breast Cancer
|
trilaciclib Sensitive: B - Late Trials
|
trilaciclib Sensitive: B - Late Trials
|
No biomarker
|
Triple Negative Breast Cancer
|
No biomarker
|
Triple Negative Breast Cancer
|
CT7001 Sensitive: B - Late Trials
|
CT7001 Sensitive: B - Late Trials
|
HR positive
|
Triple Negative Breast Cancer
|
HR positive
|
Triple Negative Breast Cancer
|
olaparib Sensitive: C1 - Off-label
|
olaparib Sensitive: C1 - Off-label
|
HRD
|
Triple Negative Breast Cancer
|
HRD
|
Triple Negative Breast Cancer
|
olaparib Sensitive: C1 - Off-label
|
olaparib Sensitive: C1 - Off-label
|
BRCA2 mutation
|
Triple Negative Breast Cancer
|
BRCA2 mutation
|
Triple Negative Breast Cancer
|
niraparib Sensitive: C1 - Off-label
|
niraparib Sensitive: C1 - Off-label
|
BRCA1 mutation
|
Triple Negative Breast Cancer
|
BRCA1 mutation
|
Triple Negative Breast Cancer
|
niraparib Sensitive: C1 - Off-label
|
niraparib Sensitive: C1 - Off-label
|
TMB-H
|
Triple Negative Breast Cancer
|
TMB-H
|
Triple Negative Breast Cancer
|
pembrolizumab Sensitive: C1 - Off-label
|
pembrolizumab Sensitive: C1 - Off-label
|
BRCA1 mutation
|
Triple Negative Breast Cancer
|
BRCA1 mutation
|
Triple Negative Breast Cancer
|
rucaparib Sensitive: C1 - Off-label
|
rucaparib Sensitive: C1 - Off-label
|
PD-L1 expression
|
Triple Negative Breast Cancer
|
PD-L1 expression
|
Triple Negative Breast Cancer
|
durvalumab Sensitive: C1 - Off-label
|
durvalumab Sensitive: C1 - Off-label
|
BRCA2 mutation
|
Triple Negative Breast Cancer
|
BRCA2 mutation
|
Triple Negative Breast Cancer
|
pamiparib Sensitive: C1 - Off-label
|
pamiparib Sensitive: C1 - Off-label
|
BRCA1 mutation
|
Triple Negative Breast Cancer
|
BRCA1 mutation
|
Triple Negative Breast Cancer
|
pamiparib Sensitive: C1 - Off-label
|
pamiparib Sensitive: C1 - Off-label
|
BRAF V600E
|
Triple Negative Breast Cancer
|
BRAF V600E
|
Triple Negative Breast Cancer
|
vemurafenib Sensitive: C1 - Off-label
|
vemurafenib Sensitive: C1 - Off-label
|
BRCA2 mutation
|
Triple Negative Breast Cancer
|
BRCA2 mutation
|
Triple Negative Breast Cancer
|
rucaparib Resistant: C1 - Off-label
|
rucaparib Resistant: C1 - Off-label
|
BRCA1 mutation
|
Triple Negative Breast Cancer
|
BRCA1 mutation
|
Triple Negative Breast Cancer
|
tislelizumab + pamiparib Sensitive: C2 – Inclusion Criteria
|
tislelizumab + pamiparib Sensitive: C2 – Inclusion Criteria
|
PTEN-L
|
Triple Negative Breast Cancer
|
PTEN-L
|
Triple Negative Breast Cancer
|
RG7440 Sensitive: C2 – Inclusion Criteria
|
RG7440 Sensitive: C2 – Inclusion Criteria
|
PD-L1 expression
|
Triple Negative Breast Cancer
|
PD-L1 expression
|
Triple Negative Breast Cancer
|
trilaciclib Sensitive: C2 – Inclusion Criteria
|
trilaciclib Sensitive: C2 – Inclusion Criteria
|
AR positive
|
Triple Negative Breast Cancer
|
AR positive
|
Triple Negative Breast Cancer
|
enzalutamide capsule Sensitive: C2 – Inclusion Criteria
|
enzalutamide capsule Sensitive: C2 – Inclusion Criteria
|
PD-L1 expression
|
Triple Negative Breast Cancer
|
PD-L1 expression
|
Triple Negative Breast Cancer
|
avelumab Sensitive: C2 – Inclusion Criteria
|
avelumab Sensitive: C2 – Inclusion Criteria
|
PD-L1 expression
|
Triple Negative Breast Cancer
|
PD-L1 expression
|
Triple Negative Breast Cancer
|
olaparib + durvalumab + cediranib Sensitive: C2 – Inclusion Criteria
|
olaparib + durvalumab + cediranib Sensitive: C2 – Inclusion Criteria
|
AR positive
|
Triple Negative Breast Cancer
|
AR positive
|
Triple Negative Breast Cancer
|
darolutamide Sensitive: C2 – Inclusion Criteria
|
darolutamide Sensitive: C2 – Inclusion Criteria
|
BRCA1 mutation
|
Triple Negative Breast Cancer
|
BRCA1 mutation
|
Triple Negative Breast Cancer
|
olaparib + durvalumab Sensitive: C2 – Inclusion Criteria
|
olaparib + durvalumab Sensitive: C2 – Inclusion Criteria
|
HRD
|
Triple Negative Breast Cancer
|
HRD
|
Triple Negative Breast Cancer
|
tislelizumab Sensitive: C2 – Inclusion Criteria
|
tislelizumab Sensitive: C2 – Inclusion Criteria
|
BRCA2 mutation
|
Triple Negative Breast Cancer
|
BRCA2 mutation
|
Triple Negative Breast Cancer
|
tislelizumab Sensitive: C2 – Inclusion Criteria
|
tislelizumab Sensitive: C2 – Inclusion Criteria
|
BRCA2 mutation
|
Triple Negative Breast Cancer
|
BRCA2 mutation
|
Triple Negative Breast Cancer
|
durvalumab Sensitive: C2 – Inclusion Criteria
|
durvalumab Sensitive: C2 – Inclusion Criteria
|
PD-L1 expression
|
Triple Negative Breast Cancer
|
PD-L1 expression
|
Triple Negative Breast Cancer
|
toripalimab Sensitive: C2 – Inclusion Criteria
|
toripalimab Sensitive: C2 – Inclusion Criteria
|
TP53 mutation
|
Triple Negative Breast Cancer
|
TP53 mutation
|
Triple Negative Breast Cancer
|
AZD1775 Sensitive: C2 – Inclusion Criteria
|
AZD1775 Sensitive: C2 – Inclusion Criteria
|
SORT1 expression
|
Triple Negative Breast Cancer
|
SORT1 expression
|
Triple Negative Breast Cancer
|
TH 1902 Sensitive: C2 – Inclusion Criteria
|
TH 1902 Sensitive: C2 – Inclusion Criteria
|
HR positive
|
Triple Negative Breast Cancer
|
HR positive
|
Triple Negative Breast Cancer
|
pembrolizumab Sensitive: C2 – Inclusion Criteria
|
pembrolizumab Sensitive: C2 – Inclusion Criteria
|
HRD
|
Triple Negative Breast Cancer
|
HRD
|
Triple Negative Breast Cancer
|
cisplatin Sensitive: C2 – Inclusion Criteria
|
cisplatin Sensitive: C2 – Inclusion Criteria
|
TLE3 expression
|
Triple Negative Breast Cancer
|
TLE3 expression
|
Triple Negative Breast Cancer
|
eribulin mesylate Sensitive: C3 – Early Trials
|
eribulin mesylate Sensitive: C3 – Early Trials
|
AKT1 amplification
|
Triple Negative Breast Cancer
|
AKT1 amplification
|
Triple Negative Breast Cancer
|
AN2025 Sensitive: C3 – Early Trials
|
AN2025 Sensitive: C3 – Early Trials
|
AKT1 E17K
|
Triple Negative Breast Cancer
|
AKT1 E17K
|
Triple Negative Breast Cancer
|
AN2025 Sensitive: C3 – Early Trials
|
AN2025 Sensitive: C3 – Early Trials
|
PIK3CA mutation
|
Triple Negative Breast Cancer
|
PIK3CA mutation
|
Triple Negative Breast Cancer
|
everolimus Sensitive: C3 – Early Trials
|
everolimus Sensitive: C3 – Early Trials
|
PALB2 mutation
|
Triple Negative Breast Cancer
|
PALB2 mutation
|
Triple Negative Breast Cancer
|
everolimus Sensitive: C3 – Early Trials
|
everolimus Sensitive: C3 – Early Trials
|
BRCA2 mutation
|
Triple Negative Breast Cancer
|
BRCA2 mutation
|
Triple Negative Breast Cancer
|
gemcitabine + eribulin mesylate Resistant: C3 – Early Trials
|
gemcitabine + eribulin mesylate Resistant: C3 – Early Trials
|
BRCA1 mutation
|
Triple Negative Breast Cancer
|
BRCA1 mutation
|
Triple Negative Breast Cancer
|
gemcitabine + eribulin mesylate Resistant: C3 – Early Trials
|
gemcitabine + eribulin mesylate Resistant: C3 – Early Trials
|
AR positive
|
Triple Negative Breast Cancer
|
AR positive
|
Triple Negative Breast Cancer
|
palbociclib Sensitive: C3 – Early Trials
|
palbociclib Sensitive: C3 – Early Trials
|
CD47 overexpression
|
Triple Negative Breast Cancer
|
CD47 overexpression
|
Triple Negative Breast Cancer
|
VT1021 Sensitive: C3 – Early Trials
|
VT1021 Sensitive: C3 – Early Trials
|
BRCA1 mutation
|
Triple Negative Breast Cancer
|
BRCA1 mutation
|
Triple Negative Breast Cancer
|
pembrolizumab + niraparib Sensitive: C3 – Early Trials
|
pembrolizumab + niraparib Sensitive: C3 – Early Trials
|
BRCA2 mutation
|
Triple Negative Breast Cancer
|
BRCA2 mutation
|
Triple Negative Breast Cancer
|
pembrolizumab + niraparib Sensitive: C3 – Early Trials
|
pembrolizumab + niraparib Sensitive: C3 – Early Trials
|
PD-L1 underexpression
|
Triple Negative Breast Cancer
|
PD-L1 underexpression
|
Triple Negative Breast Cancer
|
atezolizumab + RG6180 Sensitive: C3 – Early Trials
|
atezolizumab + RG6180 Sensitive: C3 – Early Trials
|
PTEN mutation
|
Triple Negative Breast Cancer
|
PTEN mutation
|
Triple Negative Breast Cancer
|
pembrolizumab Resistant: C3 – Early Trials
|
pembrolizumab Resistant: C3 – Early Trials
|
PTEN mutation
|
Triple Negative Breast Cancer
|
PTEN mutation
|
Triple Negative Breast Cancer
|
atezolizumab Resistant: C3 – Early Trials
|
atezolizumab Resistant: C3 – Early Trials
|
TMB-H
|
Triple Negative Breast Cancer
|
TMB-H
|
Triple Negative Breast Cancer
|
atezolizumab Sensitive: C3 – Early Trials
|
atezolizumab Sensitive: C3 – Early Trials
|
PD-L1 overexpression
|
Triple Negative Breast Cancer
|
PD-L1 overexpression
|
Triple Negative Breast Cancer
|
olaparib Sensitive: C3 – Early Trials
|
olaparib Sensitive: C3 – Early Trials
|
FOXA1 overexpression
|
Triple Negative Breast Cancer
|
FOXA1 overexpression
|
Triple Negative Breast Cancer
|
carboplatin + docetaxel Resistant: C3 – Early Trials
|
carboplatin + docetaxel Resistant: C3 – Early Trials
|
AR overexpression
|
Triple Negative Breast Cancer
|
AR overexpression
|
Triple Negative Breast Cancer
|
TAK 700 Sensitive: C3 – Early Trials
|
TAK 700 Sensitive: C3 – Early Trials
|